通尿灵治疗前列腺增生症临床疗效观察

目的：验证通尿灵治疗前列腺增生症（ＢＰＨ）的临床疗效。方法：选择经临床确诊的ＢＰＨ患者５９例，口服通尿灵５０ｍｇ，２次／ｄ，共８周。分别于用药前，治疗后４周及８周行国际前列腺症状评分，尿流率，残余尿量，血清前列腺特异性抗原（ＰＳＡ０及前列腺体积等指标测定，同时对出现的副作用进行记录。

Clinical effects of tadenan on benign prostate hypertrophy

Purpose: To verify the clinical effects of tadenan on benign prostate hypertrophy (BPH). Methods: 59 cases of BPH as diagnosed were selected.tadenan was administered orally with the recommended dose of 50 mg,twice daily over 8 weeks.IPSS, urine flow rate,residual urine volume,PSA and prostate volume were measured and the drug side effects were recorded before,4 weeks and 8 weeks after administration respectively. Results: 8 weeks after administration,on an average,IPSS decreased by 6.23,urine flow rate increased by4.8ml/s,residual urine volume reduced by 21.79 ml,PSA decreased to normal,prostate volume changed little.1 among 59 cases appeared mild gastrointestinal disturbance. Conclusions: tadenan can dramatically improve symptoms,signs and life qualities of patients with BPH.The side effects attributed to tadenan are less common.